Senseonics Holdings, Inc. Common Stock (SENS) - Total Liabilities
Based on the latest financial reports, Senseonics Holdings, Inc. Common Stock (SENS) has total liabilities worth $61.76 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Senseonics Holdings, Inc. Common Stock to assess how effectively this company generates cash.
Senseonics Holdings, Inc. Common Stock - Total Liabilities Trend (2013–2024)
This chart illustrates how Senseonics Holdings, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check Senseonics Holdings, Inc. Common Stock asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Senseonics Holdings, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Senseonics Holdings, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bermaz Auto Bhd
KLSE:5248
|
Malaysia | RM850.60 Million |
|
Oxley Bridge Acquisition Limited Class A Ordinary Shares
NASDAQ:OBA
|
USA | $8.76 Million |
|
PAN Group JSC
VN:PAN
|
Vietnam | ₫6.62 Trillion |
|
Horizon Oil Ltd
AU:HZN
|
Australia | AU$114.86 Million |
|
AK Sigorta AS
IS:AKGRT
|
Turkey | TL22.70 Billion |
|
Beacon Lighting Group Ltd
AU:BLX
|
Australia | AU$212.17 Million |
|
MSP Steel & Power Limited
NSE:MSPL
|
India | Rs5.90 Billion |
|
M3-Brigade Acquisition V Corp. Units
NASDAQ:MBAVU
|
USA | $20.70 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Senseonics Holdings, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Senseonics Holdings, Inc. Common Stock.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Senseonics Holdings, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Senseonics Holdings, Inc. Common Stock (2013–2024)
The table below shows the annual total liabilities of Senseonics Holdings, Inc. Common Stock from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $116.99 Million | +14.22% |
| 2023-12-31 | $102.42 Million | -43.18% |
| 2022-12-31 | $180.25 Million | -53.12% |
| 2021-12-31 | $384.46 Million | +113.59% |
| 2020-12-31 | $180.00 Million | +27.25% |
| 2019-12-31 | $141.45 Million | +59.45% |
| 2018-12-31 | $88.71 Million | +129.37% |
| 2017-12-31 | $38.68 Million | +42.47% |
| 2016-12-31 | $27.15 Million | +78.73% |
| 2015-12-31 | $15.19 Million | +25.72% |
| 2014-12-31 | $12.08 Million | +413808.87% |
| 2013-12-31 | $2.92K | -- |
About Senseonics Holdings, Inc. Common Stock
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabet… Read more